Abstract:e14513 Background: Local recurrence of Hepatocellular Carcinoma (HCC) following potentially curative resection or ablation is an inevitable risk. T cells recognizing neoantigens are present in most cancers including HCC and offer a specific and highly immunogenic target for the personalized vaccination as an adjuvant therapy. The purpose of this study is to evaluate the safety and T cell immune response of a personalized neoantigen-based mRNA loaded dendritic cell (DC) vaccine (LK101) combined with regular ablation in patients with HCC (NCT03674073). Methods: Each patient’s fresh tumor biopsy and matched peripheral blood sample were subjected to whole-exome sequencing and RNA-sequencing. Following determination of somatic mutations and gene expression, up to 30 in silico–predicted potential neoantigens were selected with bioinformatic tool. DCs were generated from the monocytes enriched by leukapheresis, followed by transfection with neoantigen-encoding mRNA through electroporation. In total, 7 doses of LK101 were administered at 1.5×107 cells/injection intradermally with 4-dose priming weekly and 3 boosters in 4-week intervals. The primary endpoint of the clinical study was safety, and key secondary endpoints were immunogenicity, overall survival and recurrence. 24 HCC patients at HKLC stage IIa were enrolled 1:1 to ablation control arm and ablation combined with DC (LK101) arm. Results: The study was completed, patients were followed up for a median of 48.4 months and 38.8 months in vaccination arm and control arm. All of adverse events were Grade 1-2. Most frequent treatment-related adverse events are injection site reactions, inclusive of local pain (63.6%), itch (27.3%) and others (27.3%), such as redness and edema. 3 patients in ablation control arm died, whereas all vaccinated patients survived. The 1-year and 2-year recurrence rates in vaccination arm compared with control arm are 18.2%, respectively. LK101 induced neoantigen-specific T cell responses were investigated by ELISpot analysis. Overall, all patients elicited at least one measurable response. Immune responses to 60-90% of neoantigen peptides were seen post vaccination across patients. Both preexisting immune response and De Novo immune response that targeted neoantigens were observed in vaccinated patients. Moreover, both CD4 and CD8 positive effector memory T cells showed the trend of increase, and PD-1 positive T cells reduced in peripheral blood of patients after vaccination. Conclusions: Combination of LK101 with ablation therapy has a manageable safety profile, showing the evidence of immune activation and potential of prolonged survival. In combination with regular ablation, neoantigen based mRNA loaded DC vaccine is a promising immunotherapy for the treatment of HCC. Clinical trial information: NCT03674073 .

Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma

Eliciting specific antitumor immunity against hepatocellular carcinoma in vitro by fusions of HCC patient-derived dendritic cells with HCC cells

Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.

Antitumor Effect of Immunization with Fusion of Dendritic Cells and Hepatocellular Carcinoma Cells in Mice.

A First-in-human Study to Evaluate a Personalized Neoantigen-Based Mrna-Loaded Dendritic Cell Vaccine, in Combination with Ablation, in Patients with Hepatocellular Carcinoma.

Apoptosis Effect of Immunizations with Fusions of Dendritic Cells and HCC Cells in Mice

[Inducing Hepatocellular Carcinoma-Specific Cytotoxic T Lymphocyte Response Using Formed by Fusion of FastDCs and Allogeneic Human Hepatocellular Carcinoma Cells].

Dendritic Cells Pulsed with Α‐fetoprotein and Mutant P53 Fused Gene Induce Bi‐targeted Cytotoxic T Lymphocyte Response Against Hepatic Carcinoma

Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma

Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine.

Comparative Analysis of Cytotoxic T Lymphocyte Response Induced by Dendritic Cells Pulsed with Recombinant Adeno-Associated Virus Carrying Α-Fetoprotein Gene or Cancer Cell Lysate.

Patient-derived Renal Cell Carcinoma Cells Fused with Allogeneic Dendritic Cells Elicit Anti-Tumor Activity: in Vitro Results and Clinical Responses

[Antitumor Response Induced by Vaccine of Autologous Dendritic/tumor Fusion Cells Against Renal Cell].

Dendritic cells transfected with tumor total RNA induce specific immune responses against hepatocellular carcinoma in vitro

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity

Immunotherapy of Patient with Hepatocellular Carcinoma Using Cytotoxic T Lymphocytes Ex Vivo Activated with Tumor Antigen-Pulsed Dendritic Cells